R
Rosa Lamarca
Researcher at AstraZeneca
Publications - 30
Citations - 1261
Rosa Lamarca is an academic researcher from AstraZeneca. The author has contributed to research in topics: Aclidinium bromide & Budesonide/formoterol. The author has an hindex of 9, co-authored 30 publications receiving 964 citations.
Papers
More filters
Journal ArticleDOI
Inhaled Combined Budesonide-Formoterol as Needed in Mild Asthma.
Paul M. O'Byrne,J. Mark FitzGerald,Eric D. Bateman,Peter J. Barnes,Nanshan Zhong,Christina Keen,Carin Jorup,Rosa Lamarca,Stefan Ivanov,Helen K. Reddel +9 more
TL;DR: In patients with mild asthma, as‐needed budesonide–formoterol provided superior asthma‐symptom control to as‐ needed terbutaline, assessed according to electronically recorded weeks with well‐controlled asthma, but was inferior to budesonid maintenance therapy.
Journal ArticleDOI
As-Needed Budesonide–Formoterol versus Maintenance Budesonide in Mild Asthma
Eric D. Bateman,Helen K. Reddel,Paul M. O'Byrne,Peter J. Barnes,Nanshan Zhong,Christina Keen,Carin Jorup,Rosa Lamarca,Agnieszka Siwek-Posluszna,J. Mark FitzGerald +9 more
TL;DR: In patients with mild asthma, budesonide–formoterol used as needed was noninferior to twice‐daily budesonides maintenance therapy with respect to the rate of severe asthma exacerbations during 52 weeks of treatment but was inferior in controlling symptoms.
Journal ArticleDOI
Efficacy and safety of twice-daily aclidinium bromide in COPD patients: The ATTAIN study
Paul W. Jones,Dave Singh,Eric D. Bateman,Alvar Agusti,Rosa Lamarca,Gonzalo de Miquel,Rosa Segarra,Cynthia Caracta,Esther Garcia Gil +8 more
TL;DR: Twice-daily aclidinium significantly improved bronchodilation, health status and dyspnoea, and was well tolerated in patients with COPD.
Journal ArticleDOI
Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease
Paul W. Jones,Stephen I. Rennard,Alvar Agusti,Pascal Chanez,Helgo Magnussen,Leonardo M. Fabbri,James F. Donohue,Eric D. Bateman,Nicholas J. Gross,Rosa Lamarca,Cynthia Caracta,Esther Garcia Gil +11 more
TL;DR: Aclidinium is effective and well tolerated in patients with moderate to severe chronic obstructive pulmonary disease and time to first moderate or severe COPD exacerbation is significantly delayed in ACCLAIM/COPD II.
Journal ArticleDOI
Characterisation and impact of reported and unreported exacerbations: results from ATTAIN.
Paul W. Jones,Rosa Lamarca,Ferran Chuecos,Dave Singh,Alvar Agusti,Eric D. Bateman,Gonzalo de Miquel,Cynthia Caracta,Esther Garcia Gil +8 more
TL;DR: The frequency and impact of exacerbations identified using healthcare resource utilisation (HCRU) or the EXAcerbations of Chronic pulmonary disease Tool (EXACT) were compared prospectively in a 24-week trial (ATTAIN).